工程化IL7受体的组成性信号促进肿瘤重定向T细胞持久消除肿瘤
为克服外源性细胞因子毒性的限制,构建了不依赖胞外细胞因子即可触发IL7信号的组成性信号受体C7R,与肿瘤导向CAR共表达后增强T细胞增殖、存活和抗肿瘤活性;在转移性神经母细胞瘤和原位胶质母细胞瘤异种移植模型中,C7R共表达CAR T细胞在无C7R支持时无效的细胞剂量下仍有活性。
要点
- C7R是一种组成性信号细胞因子受体,可触发IL7信号轴但不响应胞外细胞因子。
- C7R与肿瘤导向CAR共表达可增强T细胞增殖、存活和抗肿瘤活性,不导致T细胞功能障碍或自主生长。
- C7R共表达CAR T细胞在转移性神经母细胞瘤和原位胶质母细胞瘤异种移植模型中,于无C7R支持时无效的细胞剂量下仍有活性。
核心结论
- C7R可能增强针对癌症的抗原特异性T细胞治疗。
研究设计与样本
- 临床前研究:构建组成性信号细胞因子受体C7R,与肿瘤导向嵌合抗原受体共表达,在重复暴露于肿瘤细胞及转移性神经母细胞瘤和原位胶质母细胞瘤异种移植模型中评估T细胞功能。
主要发现
- C7R与肿瘤导向CAR共表达增加T细胞增殖、存活和抗肿瘤活性,且不导致T细胞功能障碍或自主T细胞生长。
- C7R共表达CAR T细胞在转移性神经母细胞瘤和原位胶质母细胞瘤异种移植模型中,于无C7R支持时无效的细胞剂量下仍有活性。
临床怎么用
- 作者认为C7R可能增强针对癌症的抗原特异性T细胞治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Successful adoptive T-cell immunotherapy of solid tumors will require improved expansion and cytotoxicity of tumor-directed T cells within tumors. Providing recombinant or transgenic cytokines may produce the desired benefits but is associated with significant toxicities, constraining clinical use. To circumvent this limitation, we constructed a constitutively signaling cytokine receptor, C7R, which potently triggers the IL7 signaling axis but is unresponsive to extracellular cytokine. This strategy augments modified T-cell function following antigen exposure, but avoids stimulating bystander lymphocytes. Coexpressing the C7R with a tumor-directed chimeric antigen receptor (CAR) increased T-cell proliferation, survival, and antitumor activity during repeated exposure to tumor cells, without T-cell dysfunction or autonomous T-cell growth. Furthermore, C7R-coexpressing CAR T cells were active against metastatic neuroblastoma and orthotopic glioblastoma xenograft models even at cell doses that had been ineffective without C7R support. C7R may thus be able to enhance antigen-specific T-cell therapies against cancer.Significance: The constitutively signaling C7R system developed here delivers potent IL7 stimulation to CAR T cells, increasing their persistence and antitumor activity against multiple preclinical tumor models, supporting its clinical development. Cancer Discov; 7(11); 1238-47. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1201.
引用
- Shum T, Omer B, Tashiro H, et al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017. PMID: 28830878. doi:10.1158/2159-8290.CD-17-0538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。